Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (MCRPC).

According to the new European Physician & Payer Forum report entitled Will Emerging Agents for Prostate Cancer Achieve Acceptance from Payers and Prescribers in Europe?, surveyed oncologists in France, Germany, Italy, Spain and the United Kingdom say that efficacy is overwhelmingly the most important factor dictating the uptake of emerging therapies for MCRPC.

"Emerging agents need to improve efficacy over current standards of care in order to penetrate the market," said Decision Resources Analyst Andrew Merron, Ph.D. "The barrier is lower in the asymptomatic MCRPC setting where clinicians are dependent on hormonal therapies, while barriers are greater in the symptomatic MCRPC setting where Sanofi-Aventis's Taxotere (docetaxel), the gold-standard, is widely prescribed. As a result, most agents in clinical trials are being used in combination with Taxotere for symptomatic MCRPC."

In symptomatic MCRPC, the majority of patients will receive a Taxotere-containing regimen one year following the launch of emerging therapies. Celgene's Revlimid and Bristol-Myers Squibb's Sprycel and zibotentan will compete to partner with Taxotere. After considering reimbursement hurdles in their countries, overall, French and Italian oncologists assign the greatest patient share to Sprycel and zibotentan. However, the greatest patient share of any regimen will be attributed to Taxotere/prednisone alone with no emerging therapy additions.

In non-metastatic castrate-resis
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MENLO PARK, Calif. , Aug. 27, 2014 /PRNewswire/ ... of advanced cancer therapeutics , will be featured as ... Renshaw Global Investment Conference, sponsored by H.C. Wainwright ... September 9th at 2:55 p.m. EDT in the Kennedy ... Hotel in New York City . ...
(Date:8/27/2014)... Aug. 27, 2014 About 8 million Americans ... to buildup of fatty plaque in the arteries, according ... patient population and in incidences of diabetes and obesity, ... Lower Extremity Arterial RevascularizatioN (LEARN) meeting, Oct. ... specialists and interested residents and fellows will be able ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Oximeter Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The pulse oximeter market analysis is provided for the ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Global Pulse Oximeter Industry Report 2014 2
(Date:8/27/2014)... August 27, 2014 Sound Telecom, a ... solutions, and cloud-based business communication systems, has unveiled an ... about HIPAA-compliant Secure Text Messaging .” The piece examines ... need to do to remain compliant with HIPAA and ... the article and C.O.O. at Sound Telecom, opens with ...
(Date:8/27/2014)... August 27, 2014 Dr. Stewart ... Center see multitudes of patients suffering from impaired vision. ... Cataract vision correction surgery . Recently, Dr. Shofner ... information during an eye exam and also online. To ... top five myths about glaucoma. , 1)    Myth: People with ...
(Date:8/27/2014)... ANS is pleased to ... anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). ... new medical therapy and will begin extending this new ... NovoTTF™ Therapy is a portable, non-invasive anti-mitotic system approved ... age and older. It is a treatment option for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The federal ... http://www.consumerinjurylawyers.com/DePuy/ ) has extended the deadline for plaintiffs to ... August 2014 Order issued by U.S. District Judge David ... to enroll in the DePuy ASR Settlement Program must ... Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – ...
(Date:8/27/2014)... August 27, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, reports ... for discovery procedures, specifically Collection and Preservation of Evidence, ... transvaginal mesh devices. (MDL No. 2187, In Re: C.R. ... United States District Court, Southern District or West Virginia; ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... BEIJING, June 9 /PRNewswire-Asia/ -- RainEarth ... its,contractual partner in China, Beijing RainEarth Technology Co. Ltd., ... generation of,blood dialysis. , This ... These include: a lower broken membrane rate, a higher ...
... and Disability products, vision and dental expand cost-effective solutions ... June 9 Empire BlueCross BlueShield (Empire) today announced ... begin offering Life and Disability insurance as part of ... affiliate, Anthem Life & Disability Insurance Company, this addition ...
... 9 In his Saturday weekly radio address, President Obama referred to ... untrue. , , The truth is that healthcare spending ... increased by 10% in 1970 and 13% in 1980. But over ... reached a low of 6% in 2007. For more of ...
... solutions while asleep, study suggests , TUESDAY, June 9 (HealthDay ... sleep on it, researchers suggest. , In a study from ... researchers say that rapid eye movement (REM) sleep boosts ... the brain. , "We found that -- for creative problems ...
... Less Than One in Five Employers Offer Stand Alone Vision ... VSP(R) Vision Care launched the industry,s first ... it grow to more than 25,000 members nationwide. In a ... economy on health and vision care priorities and costs, VSP ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... the trade. Calcitonin-salmon nasal spray is a generic version ... Miacalcin were approximately $112 million in 2008, according to IMS ... about calcitonin-salmon nasal spray , , Calcitonin-salmon nasal ...
Cached Medicine News:Health News:RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment 2Health News:RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment 3Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 2Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 3Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 4Health News:Got a Problem? Think About It Overnight 2Health News:VSP's Individual Plan Thrives in a Starving Economy 2Health News:VSP's Individual Plan Thrives in a Starving Economy 3Health News:Par Pharmaceutical Begins Shipment of Generic Miacalcin(R) 2
... innovator of suction products in the U.S. ... and assure that their quality meets or ... and directly support our full line of ... and Poole Tip Suction handles, suction canisters, ...
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Medicine Products: